DA5221-B1

Dong-A ST Co., Ltd. · Phase 3 active Small molecule

DA5221-B1 is a therapeutic candidate in phase 3 development by Dong-A ST Co., Ltd., but its specific mechanism of action is not publicly disclosed.

At a glance

Generic name	DA5221-B1
Sponsor	Dong-A ST Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Without access to detailed clinical trial data or company disclosures, the precise molecular mechanism cannot be reliably determined. Phase 3 status indicates the drug has demonstrated sufficient efficacy and safety in phase 2 to warrant late-stage clinical testing, but the mechanism remains proprietary or undisclosed in available public sources.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DA5221-B1 CI brief — competitive landscape report
DA5221-B1 updates RSS · CI watch RSS
Dong-A ST Co., Ltd. portfolio CI